Polatuzumab Vedotin in a Patient with Refractory Burkitt Lymphoma, a Case Report.

Autor: Alanzi M; Department of Internal Medicine, Hamad Medical Corporation, Doha, Qatar., Abu-Tineh M; Department of Medical Oncology/Hematology, National Center for Cancer Care and Research, Doha, Qatar., Szabados L; Department of Nuclear Medicine, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar., Sharaf Eldean MZ; Department of Pathology, Hamad Medical Corporation, Doha, Qatar., Alatasi S; Department of Pathology, Hamad Medical Corporation, Doha, Qatar., Taha RY; Department of Medical Oncology/Hematology, National Center for Cancer Care and Research, Doha, Qatar., Elkourashy SA; Department of Medical Oncology/Hematology, National Center for Cancer Care and Research, Doha, Qatar.; Weill Cornell Medicine University, Doha, Qatar.
Jazyk: angličtina
Zdroj: OncoTargets and therapy [Onco Targets Ther] 2023 Feb 21; Vol. 16, pp. 133-139. Date of Electronic Publication: 2023 Feb 21 (Print Publication: 2023).
DOI: 10.2147/OTT.S394193
Abstrakt: Although Burkitt lymphoma is considered a curable disease due to the progress made in choosing the most effective first-line therapy, relapsed or refractory Burkitt lymphoma (BL) has a very poor outcome. There is a lack of data supporting the treatment regimens. We report a 48-year-old male with stage II Burkitt's lymphoma with no response to the first line of high-intensity chemotherapy. However, treatment with polatuzumab vedotin led to complete clinical remission for more than one year.
Competing Interests: The authors report no conflicts of interest in this work.
(© 2023 Alanzi et al.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje